Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
09:11am, Wednesday, 28'th Feb 2024
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.44 per share a year ago.
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
07:00am, Wednesday, 28'th Feb 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics to Present at Upcoming Investor Conferences
08:01am, Tuesday, 27'th Feb 2024
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
08:00am, Wednesday, 21'st Feb 2024
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
11:06am, Tuesday, 20'th Feb 2024
Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference
08:00am, Thursday, 01'st Feb 2024
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
05:41pm, Monday, 22'nd Jan 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with substantial catalysts and make a fortune.
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 01'st Dec 2023
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call Transcript
01:34pm, Tuesday, 07'th Nov 2023
Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call Transcript
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
07:00am, Tuesday, 07'th Nov 2023
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
04:30pm, Tuesday, 31'st Oct 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
08:00am, Tuesday, 31'st Oct 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)
11:05am, Friday, 18'th Aug 2023
The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall
Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround
10:59am, Wednesday, 16'th Aug 2023
The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall
